CA 19-9 in pancreatic cancer: Retrospective evaluation of patients with suspicion of pancreatic cancer

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 799-807

  Molina, Victor ^a   Visa, Laura ^a   Conill, Carles ^a   Navarro, Salvador ^a   Escudero, Jose M ^a   Auge, Jose M ^a   Filella, Xavier ^a   Lopez Boado, Miguel A ^a   Ferrer, Joana ^a   Fernandez Cruz, Laureano ^a   Molina, Rafael ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

CA 19.9; Pancreatic cancer; Tumor markers

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PERIAMPULLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VATER PAPILLA CARCINOMA; BLOOD; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SURVIVAL;

AGED; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863596203     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0297-8     Document Type: Article

References (54)

1. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226:248-57.
2. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2007;33:892-7.
3. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol. 2004;99:492-501.
4. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, European Study Group for Pancreatic Cancer, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10.
5. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10-30.
6. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high risk individuals. Clin Gastro Hepatol. 2004;2:606-21.
7. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16:37-52.
8. Duffy MH, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-7.
9. Ni XG, Bai XF, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. EJSO. 2005;31:164-9.
10. Koopmann J, Rosenzweig NW, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442-6.
11. Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology. 2005;5:576-90.
12. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas. 1994;9:731-4.
13. Ritts Jr RE, Nagorney DM, Jacobsen DJ, Talbot RW, Zurawski Jr VR. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas. 1994;9:707-16.
14. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-902.
15. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644-9.
16. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg. 2006;49:241-4.
17. Schlieman MG, Ho SH, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951-6.
18. Xi WU, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis. 2006;7:170-4.
19. Steinberg W. The clinical utility of CA 19-9 tumor-associated antigen. Am J Gastroent. 1990;85:350-5.
20. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. EJSO. 2007;33:266-70.
21. Cwik G, Wallner G, Skoczylas T, Ciechan A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141:968-73.
22. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;4:5501-3.
23. Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal. 2007;21:103-6.
24. Cantagrel W, Howaizi M, Abboura M, Sbai-Idrissi MS, Marty O, Djabbari-Sobhani M. A new cause for CA 19.9 elevation: heavy tea consumption. Gut. 2003;52:913-4.
25. Yuksel BC, Ozel H, Akin T, Avsar FM, Hengirmen S. Primary hydatid cyst of the breast with elevated CA19-9 level. AmJTrop Med Hyg. 2005;73:368-70.
26. Stieber P, Molina R, Gion M, Gressner A, Troalen F, Holdenrieder S, et al. Alternative antibody for the detection of CA 19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel DxI 800 Immunoassay system. Clin Chem LabMed. 2008;46:600-11.
27. Akdoǧan M, Sašmaz N, Kayhan B, Biyikoǧlu I, Dišibeyaz S, Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87:337-9.
28. Furuya N, Kawa S, Hasebe O, Tokoo M, Mukawa K, Maejima S, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer. 1996;73:372-6.
29. Duraker N, Hot S, Polat Y, Höbek N, Gençler N, Urhan N. CEA, CA 19.9 and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142-7.
30. Peterli R, Meyer-Wyss B, Herzog U, Tondelli P. CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr. 1999;129:77-9.
31. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182-6.
32. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinoma. Tumor Biol. 1992;13:278-86.
33. Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, et al. The value of serum CA 125and the association CA 125/CA 19-9 in endometrial cancer. Eur J Gynaecol Oncol. 1999;20:315-7.
34. Filella X, Fuster J, Molina R, Grau JJ, García-Valdecasas JC, Grande L, et al. TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. Acta Oncol. 1994;33:747-51.
35. Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, et al. Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biol. 2008;29:371-80.
36. Marrelli D, Pino E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19.9 and CA 72.4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16-9.
37. NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma vs 1.2012. 2011; http://www.nccn.org/professionals/physician-gls/PDF/ pancreatxsic.pdf
38. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485-89.
39. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94:1941-6.
40. Murohisa T, Sugaya H, Tetsuka I, Suzuki T, Harada T. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern Med. 1992;31:516-20.
41. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12:1068-73.
42. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int. 2007;6:641-5.
43. Haglund C, Lindgren J, Roberts PJ, Nordling S. Gastrointestinal cancer-associated CA 19.9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer. 1986;53:189-95.
44. Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta H, et al. Serum CA 19.9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer. 1986;57:1324-6.
45. Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas. 2004;28:235-40.
46. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas. 2008;28:263-7.
47. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:539-4.
48. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum Ca 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6:462-8.
49. Lundin J, Roberts P, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-9.
50. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas. 1994;9:735-40.
51. Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393-6.
52. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-38.
53. Maisey NR, Norman AR, Hill A, Massey AJ, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-3.
54. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32:35-41.